Lithium Carbonate

Phase 4 승인됨 Small molecule
Half-Life
18-36 hours
Bioavailability
Protein Binding
Molecular Weight
73.9 g/mol
LogP
Phase
4

Delivered as a simple carbonate salt (Li2CO3), lithium is the lightest metallic element to serve as a medicine, and it remains a benchmark mood stabilizer. It treats and helps prevent the manic and depressive episodes of bipolar disorder, acting through modulation of intracellular signaling, including effects on inositol turnover and inhibition of the enzyme GSK-3. Because it is a small ion (molecular weight near 74) that is filtered and handled by the kidneys much like sodium, its blood level is sensitive to hydration, salt intake, and renal function, and it carries a narrow margin between therapeutic and toxic concentrations. A half-life of roughly 18 to 36 hours and routine level monitoring characterize its use. Lithium is an approved agent that has anchored bipolar treatment for generations.

A mood-stabilizing element used as lithium salts to treat and prevent episodes of mania, depression, and bipolar disorder, and studied for potential neuroprotective effects in Alzheimer's disease. It modulates multiple neurotransmitter systems and intracellular signaling pathways.

분자량

73.8910 g/mol

TPSA

0.00 Ų

치료 영역

약물 분류

작용 기전

Modulates intracellular signaling via inositol and GSK-3 inhibition.

Pharmacokinetics (PK)

Half-Life 18-36 hours

Pharmacodynamics (PD)

기전

Modulates intracellular signaling via inositol and GSK-3 inhibition.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[Li]

InChI

InChI=1S/Li

Molecular Formula

Li2CO3

HBD / HBA

- / -

회전 가능 결합

0

무거운 원자

1

Major Lithium Carbonate + Ramipril

Ramipril, an ACE inhibitor, reduces lithium renal clearance through decreased glomerular filtration, leading to potentially toxic lithium accumulation.

Major Lithium Carbonate + Spironolactone

Spironolactone increases renal lithium reabsorption by promoting distal tubular sodium retention, leading to lithium toxicity.

Major Lithium Carbonate + Naproxen

Naproxen, like all NSAIDs, reduces renal prostaglandin synthesis, impairing lithium excretion and causing lithium toxicity.

Major Lithium Carbonate + Furosemide

Furosemide-induced sodium depletion stimulates compensatory proximal tubular reabsorption of both sodium and lithium, raising lithium levels into the toxic range.

Major Lithium Carbonate + Lisinopril

ACE inhibitors like lisinopril reduce renal lithium excretion, causing potentially dangerous lithium toxicity.

Major Lithium Carbonate + Hydrochlorothiazide

Thiazide diuretics increase lithium reabsorption in the proximal renal tubule, reliably causing lithium toxicity without dose adjustment.

Major Lithium Carbonate + Ibuprofen

NSAIDs markedly increase lithium plasma levels, potentially causing lithium toxicity (tremor, ataxia, confusion, cardiac arrhythmias).

Moderate Lithium Carbonate + Escitalopram

Escitalopram combined with lithium may augment serotonergic neurotransmission, increasing the risk of serotonin syndrome particularly at higher doses.

Moderate Lithium Carbonate + Diltiazem

Diltiazem (calcium channel blocker) combined with lithium may increase risk of lithium toxicity and neurotoxic adverse effects including bradycardia.

Moderate Lithium Carbonate + Fluoxetine

Concurrent fluoxetine and lithium may increase serotonin syndrome risk; fluoxetine may also alter lithium pharmacokinetics in some patients.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A mood-stabilizing element used as lithium salts to treat and prevent episodes of mania, depression, and bipolar disorder, and studied for potential neuroprotective effects in Alzheimer's disease. It modulates multiple neurotransmitter systems and intracellular signaling pathways.

Modulates intracellular signaling via inositol and GSK-3 inhibition.

Key pharmacokinetic parameters for Lithium Carbonate: Half-life: 18-36 hours.

Yes, Lithium Carbonate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • PubChem — National Center for Biotechnology Information (NCBI). CID 3028194. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.